FBR Capital Upgrades AMAG Pharmaceuticals To Outperform
Analysts at FBR Capital upgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Market Perform to Outperform.
The target price for AMAG Pharmaceuticals has been raised from $21 to $36.
AMAG Pharmaceuticals shares have surged 36.08% over the past 52 weeks, while the S&P 500 index has gained 16.68% in the same period.
AMAG Pharmaceuticals' shares jumped 28.21% to close at $29.72 yesterday.
Latest Ratings for AMAG
|Jan 2017||Raymond James||Downgrades||Market Perform||Underperform|
|Jan 2017||Janney Capital||Initiates Coverage On||Buy|
|Dec 2016||Cantor Fitzgerald||Initiates Coverage On||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.